Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Dec;87(12):1280-7.
doi: 10.1111/j.1349-7006.1996.tb03144.x.

No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer

N Ohashi  1 , Y Fujiwara, N Yamaoka, O Katoh, Y Satow, M Yamakido
Affiliations

No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer

N Ohashi et al. Jpn J Cancer Res. 1996 Dec.

Abstract

Mutations and reduced expression of DNA topoisomerase I (topo I) gene have been shown to be important in the acquisition of resistance to camptothecin and its analogues in vitro, but their significance has not been verified in vivo. We investigated possible topo I gene mutations and topo I mRNA expression levels in 127 samples obtained from 56 patients with lung tumors, including patients who had developed clinical resistance to topo I inhibitors. No mutations were detected in any of the samples examined and expression levels did not differ significantly between clinically resistant cases and others. However, the topo I mRNA expression level was significantly higher in small cell lung carcinomas than in non-small cell lung carcinomas (P < 0.05). These results suggest that topo I mRNA levels may affect CPT-11 sensitivity in human lung cancer. However, topo I gene mutations and reduced topo I mRNA expression may not be the main mechanism of clinically acquired resistance to camptothecin analogues in vivo.

PubMed Disclaimer

References

    1. ) Potmesil , M.Camptothecins: from bench research to hospital wards . Cancer Res. , 54 , 1431 – 1439 ( 1994. ). - PubMed
    1. ) Slichenmyer , W. J. , Rowinsky , E. K. , Donehower , R. C. and Kaufmann , S. H.The current status of camptothecin analogues as antitumor agents . J. Natl. Cancer Inst. , 85 , 271 – 291 ( 1993. ). - PubMed
    1. ) Giovanella , B. C. , Stehlin , J. S. , Wall , M. E. , Wani , M. C. , Nicholas , A. W. , Liu , L. F. , Silber , R. and Potmesil , M.DNA topoisomerase I‐targeted chemotherapy of human colon cancer in xenografts . Science , 246 , 1046 – 1048 ( 1989. ). - PubMed
    1. ) Husaine , I. , Mohler , J. L. , Seigler , H. F. and Besterman , J. M.Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor‐type specificity and implications for cancer chemotherapy . Cancer Res. , 54 , 539 – 546 ( 1994. ). - PubMed
    1. ) Kanzawa , F. , Sugimoto , Y. , Minato , K. , Kasahara , K. , Bungo , M. , Nakagawa , K. , Fujiwara , Y. , Liu , L. F. and Saijo , N.Establishment of a camptothecin analogue (CPT‐11)‐resistant cell line of human non‐small cell lung cancer: characterization and mechanism of resistance . Cancer Res. , 50 , 5919 – 5924 ( 1990. ). - PubMed

Publication types